Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors
MEK inhibitors (MEKi) represent innovative and promising treatments for managing manifestations of neurofibromatosis type 1 (NF1). To mitigate potential ophthalmic side effects, such as MEKi-associated retinopathy (MEKAR), patients undergoing MEKi therapy routinely receive ophthalmology evaluations....
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI AG
2024-05-01
|
| Collection: | Current Oncology |
| Sujets: | |
| Accès en ligne: | https://www.mdpi.com/1718-7729/31/5/199 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|